Renaissance Technologies LLC trimmed its stake in OraSure Technologies, Inc. (NASDAQ:OSUR) by 14.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 4,003,100 shares of the medical instruments supplier’s stock after selling 679,603 shares during the period. Renaissance Technologies LLC owned 6.60% of OraSure Technologies worth $75,498,000 at the end of the most recent reporting period.
Several other hedge funds also recently modified their holdings of OSUR. BlackRock Inc. increased its position in OraSure Technologies by 2.7% in the 4th quarter. BlackRock Inc. now owns 7,729,515 shares of the medical instruments supplier’s stock worth $145,778,000 after buying an additional 201,251 shares during the period. State Street Corp increased its position in OraSure Technologies by 6.9% in the 2nd quarter. State Street Corp now owns 1,639,620 shares of the medical instruments supplier’s stock worth $28,305,000 after buying an additional 106,326 shares during the period. Fuller & Thaler Asset Management Inc. increased its position in OraSure Technologies by 175.6% in the 3rd quarter. Fuller & Thaler Asset Management Inc. now owns 898,397 shares of the medical instruments supplier’s stock worth $20,214,000 after buying an additional 572,397 shares during the period. Russell Investments Group Ltd. increased its position in OraSure Technologies by 62.5% in the 3rd quarter. Russell Investments Group Ltd. now owns 809,158 shares of the medical instruments supplier’s stock worth $18,206,000 after buying an additional 311,232 shares during the period. Finally, Emerald Advisers Inc. PA bought a new position in OraSure Technologies in the 4th quarter worth approximately $12,518,000. 93.67% of the stock is currently owned by institutional investors and hedge funds.
Shares of OraSure Technologies stock traded down $0.38 during mid-day trading on Monday, reaching $17.68. The company had a trading volume of 69,949 shares, compared to its average volume of 663,813. The firm has a market cap of $1,101.06, a price-to-earnings ratio of 35.41, a price-to-earnings-growth ratio of 5.35 and a beta of 1.60. OraSure Technologies, Inc. has a twelve month low of $10.75 and a twelve month high of $23.01.
OraSure Technologies (NASDAQ:OSUR) last announced its quarterly earnings results on Wednesday, February 7th. The medical instruments supplier reported $0.12 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.11 by $0.01. The business had revenue of $52.00 million for the quarter, compared to analyst estimates of $50.20 million. OraSure Technologies had a return on equity of 13.09% and a net margin of 18.52%. OraSure Technologies’s quarterly revenue was up 46.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.13 EPS. sell-side analysts anticipate that OraSure Technologies, Inc. will post 0.27 EPS for the current fiscal year.
Several brokerages have recently weighed in on OSUR. BidaskClub raised OraSure Technologies from a “buy” rating to a “strong-buy” rating in a report on Thursday. ValuEngine raised OraSure Technologies from a “hold” rating to a “buy” rating in a report on Friday, March 2nd. Zacks Investment Research lowered OraSure Technologies from a “buy” rating to a “hold” rating in a report on Tuesday, February 13th. Finally, Canaccord Genuity reissued a “buy” rating and set a $24.00 price objective on shares of OraSure Technologies in a report on Friday, February 2nd. Two research analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $22.25.
In other OraSure Technologies news, Director Stephen S. Phd Tang sold 23,333 shares of the business’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $17.97, for a total value of $419,294.01. Following the transaction, the director now owns 59,749 shares of the company’s stock, valued at $1,073,689.53. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Brian Smith sold 20,000 shares of the business’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $17.97, for a total value of $359,400.00. Following the completion of the transaction, the executive vice president now directly owns 28,075 shares in the company, valued at approximately $504,507.75. The disclosure for this sale can be found here. 6.40% of the stock is owned by insiders.
ILLEGAL ACTIVITY NOTICE: This piece was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://ledgergazette.com/2018/03/19/orasure-technologies-inc-osur-holdings-trimmed-by-renaissance-technologies-llc.html.
OraSure Technologies Profile
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.